Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Micron Technology, Inc. (MU) Price & Performance

Dyne Therapeutics Inc. Common StockTrade
Micron Technology, Inc.Trade

Price performance (Past 24H)

Key statistics

Dyne Therapeutics Inc. Common Stock vs Micron Technology, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Micron Technology, Inc. trades at $875.61 (market cap $1.08T). The key difference: Micron Technology, Inc. is far larger — about 377.6× Dyne Therapeutics Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Micron Technology, Inc. for 49 Days on average.

DYNMU
Market Cap
$2.86B$1.08T
Volume
3,341,57928,906,235
Sector
HealthTechnology
52-Week High
$26.78$1.21K
52-Week Low
$14.60$191.94
Typical Hold Time
0 Days49 Days
Enterprise Value
$2.18B$1.04T
Dividend Yield
—0.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dyne Therapeutics Inc. Common Stock

Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.

The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.

Micron Technology, Inc.

Micron Technology (MU) is trading at $914.13, down 7.57% today, following strong recent performance. The stock shows robust fundamentals with a P/E of 12.82, net income margin of 63.8%, and consistent earnings beats. Technical indicators show a bullish moving average signal despite today's pullback, with support at $978. The company benefits from strong AI-driven memory demand and strategic customer agreements covering 35% of revenue through 2030.

Outlook remains positive with analyst consensus at 82.85% buy ratings and $1,590 price target. Key opportunities include sustained AI memory demand and reduced cyclicality through long-term contracts. Risks include potential growth deceleration in 2028 and market volatility. The stock's current valuation appears reasonable given strong profitability and growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DYN
100% Buy0% Sell
Avg holding period · 0 Days
MU
59% Buy41% Sell
Avg holding period · 49 Days

Top news

Latest headlines on both assets

About Dyne Therapeutics Inc. Common Stock

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.

Read more on DYN →

About Micron Technology, Inc.

Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.

Read more on MU →